38 completed, 2 unknown, 1 terminated, 1 withdrawn. 19 Phase 2, 11 Not applicable, 6 Phase 3, 5 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Not applicable | 11 | Completed 9, Unknown 1, Withdrawn 1 |
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow amprenavir: new trials by email Literature Review of amprenavir trials Research Report on amprenavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections | Phase 2 / Phase 3 | Completed | University of California, San Diego | 59 | 2007-03-01 | 2014-04-23 |
| Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2 - HIV Infections | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1578 | 2003-06-09 | 2025-12-02 | |
| Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients tipranavir, ritonavir, saquinavir - HIV Infections | Phase 2 | Completed | Boehringer Ingelheim | 328 | 2003-02-18 | 2023-12-01 |
| HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) Lamivudine, Stavudine, Didanosine - HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease | Phase 4 | Completed | Kirby Institute | 80 | 2003-02-01 | 2012-04-12 |
| Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor Amprenavir/ritonavir, Saquinavir/ritonavir - HIV Infections | Phase 2 / Phase 3 | Completed | Abbott | 16 | 2001-04-01 | 2006-07-28 |
| Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART Amprenavir/ritonavir, Saquinavir/ritonavir, Efavirenz - HIV Infections | Phase 2 | Completed | Abbott | 24 | 2001-04-01 | 2008-04-01 |
| Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers Indinavir sulfate, Ritonavir, Amprenavir - HIV Infections | Not applicable | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 90 | 2001-03-01 | 2021-11-01 |
| Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure. Amprenavir (drug), ABT-378/r (drug), Ritonavir (drug) - HIV Infections | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 100 | 2000-11-01 | 2026-06-15 |
| Once-Daily Drug Regimen for HIV-Infected Patients Amprenavir, Ritonavir, Abacavir - Acquired Immunodeficiency Syndrome, HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2000-01-01 | 2008-03-04 |
| Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine - HIV Infections | Not applicable | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 288 | 1999-10-01 | 2011-03-02 |
| A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults Enfuvirtide, Ritonavir, Abacavir sulfate - HIV Infections | Phase 2 | Completed | Hoffmann-La Roche | 68 | 1999-05-01 | 2005-11-15 |
| Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV Ritonavir, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 121 | 1999-05-01 | 2021-10-29 |
| Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults Nevirapine, Amprenavir, Abacavir - HIV Infections | Phase 1 | Terminated | Boehringer Ingelheim | 8 | 1999-04-01 | 2014-07-14 |
| A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients Abacavir sulfate, Amprenavir, Lamivudine - HIV Infections | Phase 3 | Completed | Glaxo Wellcome | 1999-04-01 | 2005-06-24 | |
| A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir Indinavir sulfate, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | Glaxo Wellcome | 100 | 1999-03-01 | 2005-06-24 |
| Drug Interactions Among Anti-HIV Agents Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir - HIV Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 1998-08-01 | 2008-03-04 |
| Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz Abacavir, Amprenavir, Efavirenz - HIV Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 1997-11-01 | 2008-03-04 |
| Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance Lopinavir/ritonavir, Ritonavir, Saquinavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 118 | 2011-03-01 | |
| An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen Abacavir sulfate, Amprenavir - HIV Infections | Not applicable | Completed | Glaxo Wellcome | 2005-06-24 | ||
| A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir Indinavir sulfate, Amprenavir, Nevirapine - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 94 | 2021-11-04 |
Showing 20 of 42. Sign in to see all of them.
HIV Infections (42) · Acquired Immunodeficiency Syndrome (2) · Lipodystrophy (2) · AIDS Dementia Complex (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · HIV-Associated Lipodystrophy Syndrome (1) · Hepatitis B (1) · Hyperlipidemias (1) · Insulin Resistance (1) · Patient Compliance (1) · Tetanus (1)
Glaxo Wellcome (16) · National Institute of Allergy and Infectious Diseases (NIAID) (16) · Abbott (2) · Boehringer Ingelheim (2) · ANRS, Emerging Infectious Diseases (1) · Gathe, Joseph, M.D. (1) · Gilead Sciences (1) · Hoffmann-La Roche (1) · Kirby Institute (1) · University of California, San Diego (1)
United States (39) · Puerto Rico (6) · France (4) · Italy (4) · Argentina (3) · Australia (3) · Brazil (3) · Canada (3) · United Kingdom (3) · Germany (2) · Poland (2) · Spain (2) · Belgium (1) · Botswana (1) · Denmark (1)
Eugene Sun, M.D. (2) · Gulick R (2) · Murphy R (2) · Scott Hammer (2) · Andrew D Carr, MD (1) · Cara Wilson (1) · David A Cooper, MD (1) · Deborah McMahon, M.D. (1) · Elizabeth Connick, MD (1) · Gene Morse (1) · Genevieve Chene, MD, PhD (1) · Gilles Raguin, MD (1) · Gregory Robbins (1) · John Mellors (1)
PMID 14668455, PMID 14668456, PMID 15060509, PMID 15187476, PMID 15456093, PMID 16048950, PMID 16048984, PMID 16103764, PMID 16267764, PMID 16470119, PMID 16810109, PMID 16816555, PMID 16988514, PMID 17662759, PMID 17726714, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19696651, PMID 20002783, PMID 20467286, PMID 20632458, PMID 21283017, PMID 21337357, PMID 21637110, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 24326304, PMID 24352352, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26918544, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30134297, PMID 30358179, PMID 30530925, PMID 30715324, PMID 31489678, PMID 32015036, PMID 32451908, PMID 33252495
R01HL065953 (1), R01MH058076 (1)